Nusano, a company that specializes in the production of radioisotopes, has officially opened its new 190,000-square-foot facility. The new site is designed to produce over 40 different types of radioisotopes used in cancer diagnostics, therapeutic treatments, and industrial applications such as long-lasting nuclear batteries. Utah Governor Spencer Cox led the ribbon-cutting ceremony, joined by Nusano employees, business leaders, and members of the community. Governor Cox remarked, “Utah has always been a place where bold ideas take root, and Nusano’s new facility is a perfect example. This work will deliver the radioisotopes needed for cancer treatment, advanced technologies, and national security. We’re incredibly proud to have another true pioneer in our innovation economy.”
Health Technology Insights: ARC At Sheba Center and Revealense Launch At-Home AI Neurological Diagnostics
The facility combines well-established scientific methods from top universities and research institutions with Nusano’s patented particle acceleration technology. This represents the first major improvement in radioisotope production in decades. Using a highly efficient linear accelerator, the system can manufacture multiple critical isotopes at the same time, a significant step forward compared to older methods.
Health Technology Insights: Nuvem Expands Leadership to Boost Community Pharmacy Model
Chris Lowe, CEO of Nusano, emphasized the importance of this new advancement. He said, “Nusano is commercializing breakthrough technologies to enable innovation, improve human health, and power exploration. From our world-class production facility in Utah, we will make radioisotopes in quantities and varieties unsurpassed by older methods. This will help address supply chain bottlenecks, support domestic manufacturing, and deliver life-changing radioisotope supplies needed for cancer care.”
Radioisotopes are a core component in radiopharmaceuticals, which play a vital role in many modern cancer treatments. However, current supply chains are often limited, affecting patient care, drug development, and clinical trials. Dr. Howard Lewin, co-founder and Chief Product Development Officer at Nusano, explained, “Today, researchers and drugmakers are working with what’s available, not necessarily what’s optimal. Our Utah facility can produce up to 12 different radioisotopes at the same time. This means we can meet the existing needs of drugmakers and at the same time enable tomorrow’s clinical breakthroughs with isotopes that would be unavailable or hard to access without Nusano’s production.”
In addition to healthcare, the new facility supports industries such as aerospace and defense. Specifically, it will help scale up the production of alpha-emitting radioisotopes used in nuclear batteries. These compact, long-lasting power sources are ideal for remote or harsh environments. Glenn Rosenthal, co-founder and Chief Technology Officer at Nusano, said, “Nuclear batteries are always-on systems built to provide power in places where it would be inconvenient or impossible to routinely swap out traditional batteries, such as remote ocean sensors or space satellites.” He also noted that the durability and efficiency of these batteries could reshape how connected devices are powered and enable deeper space exploration.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 20 August 2025
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
